Annovis Bio Inc. (ANVS) News
Filter ANVS News Items
ANVS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ANVS News Highlights
- ANVS's 30 day story count now stands at 4.
- Over the past 7 days, the trend for ANVS's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- BIO, DRUG and MCK are the most mentioned tickers in articles about ANVS.
Latest ANVS News From Around the Web
Below are the latest news stories about ANNOVIS BIO INC that investors may wish to consider to help them evaluate ANVS as an investment opportunity.
Does Annovis Bio, Inc. (ANVS) Have the Potential to Rally 178.45% as Wall Street Analysts Expect?The mean of analysts' price targets for Annovis Bio, Inc. (ANVS) points to a 178.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Are Medical Stocks Lagging McKesson (MCK) This Year?Here is how McKesson (MCK) and Annovis Bio, Inc. (ANVS) have performed compared to their sector so far this year. |
Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental IllnessesAnnovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's and Parkinson's disease announced today the filing of a patent application that extends the breadth of its platform from neurodegenerative to neuropsychiatric indications: "Treatment of mental illness via administration of buntanetap and analogues." |
ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASEAnnovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today provided a patient enrollment update for the Company's ongoing Phase 3 study of buntanetap for the treatment of Parkinson's disease ("PD"). |
Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership TeamAnnovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced key additions to its senior leadership team with the appointments of Dr. Michael Christie as Vice President of Process Chemistry and David Prohaska as Vice President of Toxicology and Pharmacology. |
2022 in Review: After two years of IPOs, the region's publicly traded life sciences firms hit tough timesAfter experiencing a dozen initial public stock offerings by companies in the region's life sciences industry in 2020 and 2021, this year no IPOs were completed by Philadelphia-area drug developers or medical device manufacturers because of the unfavorable climate on Wall Street. The down market, analysts said, drove investors away from biotech stocks to less expensive, and less risky, sectors of the economy — resulting in the lowest volume of life sciences IPOs in more than five years in 2022. One company, New Hope-based Orchestra BioMed Holdings, in July began the process of going public through a merger with a SPAC, or special purpose acquisition company, called Health Sciences Acquisition Corp 2. |
Can Annovis Bio, Inc. (ANVS) Climb 251% to Reach the Level Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 251.4% in Annovis Bio, Inc. (ANVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Wall Street Analysts Believe Annovis Bio, Inc. (ANVS) Could Rally 239%: Here's is How to TradeThe mean of analysts' price targets for Annovis Bio, Inc. (ANVS) points to a 239.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate UpdateAnnovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced third quarter financial results for the quarter ended September 30, 2022, and reviewed recent accomplishments. |
We're Not Very Worried About Annovis Bio's (NYSE:ANVS) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although... |